Molecular genetics of cardiomyopathies

Revista Espanola de Cardiologia

Volumn 55, Issue 3, 2002, Pages 292-302

  Roberts, Robert ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Dilated cardiomyopathy; Genetics; Hypertrophic cardiomyopathy; Sudden cardiac death

Indexed keywords

ACTIN; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN; TROPOMYOSIN; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 12Q; CHROMOSOME 14Q; CHROMOSOME 15Q; CHROMOSOME 19Q; CHROMOSOME 1Q; CHROMOSOME 3P; CHROMOSOME 7Q; DISEASE MODEL; EXPERIMENTAL MODEL; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENOTYPE PHENOTYPE CORRELATION; HEART DILATATION; HEREDITY; HUMAN; HUMAN CELL; HYPERTROPHIC CARDIOMYOPATHY; MOLECULAR GENETICS; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; ANIMAL; CONGESTIVE CARDIOMYOPATHY; GENETICS; GENOTYPE; HEART RIGHT VENTRICLE DYSPLASIA; MUTATION; PHENOTYPE; REVIEW; SARCOMERE; X CHROMOSOME;

ANIMALS; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; GENOTYPE; HUMANS; MUTATION; PHENOTYPE; SARCOMERES; X CHROMOSOME;

EID: 0035984747     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-8932(02)76597-4     Document Type: Article

References (75)

1. Sudden death in hypertrophic cardiomyopathy: A profile of 78 patients
2. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles
3. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy
4. Specificity of light an electron microscopic features of hypertrophic obstructive and nonobstructive cardiomyopathy: Qualitative, quantitative and etiologic aspects
5. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4,111 subjects in the CARDIA study
6. Hypertrophic cardiomyopathy and its markers in the general population. The great masquerader revisited: The Framingham Study
7. Mutations in the gene for cardiac myosinbinding protein C and late-onset familial hypertrophic cardiomyopathy
8. A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated beta-myosin heavy chain genes
9. A molecular basis for familial hypertrophic cardiomyopathy: A beta-cardiac myosin heavy chain gene missense mutation
10. Organization and sequence of human cardiac myosin binding protein C gene (MyBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy
11. Molecular genetic studies of familial hypertrophic cardiomyopathy
12. Troponin and tropomyosin: Proteins that switch on and tune in the activity of cardiac myofilaments
13. Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy
14. Alpha-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere
15. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy
16. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle
17. α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy
18. 908Leu\Val mutation in a family sudden death
19. Sudden cardiac death in patients with hypertrophic cardiomyopathy: From bench to bedside with an emphasis on genetic markers
20. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy
21. Prognostic significance of β-myosin heavy chain mutations is reflective of their hypertrophic expressivity in patients with hypertrophic cardiomyopathy
22. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy
23. Angiotensin converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death
24. 95Ala) is associated with mild cardiac hypertrophy but a high incidence of sudden death
25. Recent advances in the molecular genetics of hypertrophic cardiomyopathy
26. Molecular pathophysiology of cardiomyopathies
27. Expression of a missense mutation in the mRNA for β-myosin heavy chain in myocardial tissue in hypertrophic cardiomyopathy
28. Point mutations in human cardiac myosin heavy chain have differential effects on sarcomeric structure and assembly: An ATP binding site change disrupts both thick and think filaments, whereas hypertrophic display normal assembly
29. Expression of a mutation causing hypertrophic cardiomyopathy in adult feline cardiocytes disrupts sarcomere assembly in adult feline cardiac myocytes
30. Identification of a contractile deficit in adult cardiac myocytes expressing hypertrophic cardiomyopathy-associated mutant troponin T proteins
31. Hypertrophic cardiomyopathy mutation is expressed in mRNA of skeletal as well as cardiac muscle
32. Skeletal muscle expression and abnormal function of β-myosin in hypertrophic cardiomyopathy
33. Abnormal contractile properties of muscle fibers expressing β-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy
34. Isometric tension and mutant myosin heavy chain content in single skeletal myofibrils from hypertrophic cardiomyopathy pathies
35. Characterization of mutant myosins of dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants
36. Functional analysis of the mutations in the human cardiac β-myosin that are responsible for familial hypertrophic cardiomyopathy: Implication for the clinical outcome
37. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction
38. +2 regulation of thin filament motility
39. Three-dimensional structure of myosin subfragment-1: A molecular motor
40. 92Gln) human cardiac troponin T, known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocytes contractility
41. Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action
42. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: Insights into disease pathogenesis and troponin function
43. An α-cardiac myosin heavy chain gene mutation impairs contraction and relaxation function of cardiac myocytes
44. Malalignment of the sarcomeric filaments in hypertrophic cardiomyopathy with cardiac myosin heavy chain gene mutation
45. 178Ta radionucleide angiography, which precedes histological changes
46. The pathogenesis of familial hypertrophic cardiomyopathy: Early and evolving effects from an α-cardiac myosin heavy chain missense mutation
47. +2 sensitization and potentiation of the masimum level of myofibrilla ATase activity caused by mutations of troponin T found in familial hypertrophic cardiomyopathy
48. A mouse model of familial hypertrophic cardiomyopathy
49. Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy
50. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy
51. Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice
52. The stretch-activation response may be critical to the proper functioning of the mammalian heart
53. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy
54. Cardiac myosin heavy chains lacking the light chain binding domain cause hypertrophic cardiomyopathy in mice
55. A transgenic rabbit model for human hypertrophic cardiomyopathy
56. Decreased left ventricular ejection fraction, detected by 178TA radionuclide angiography in transgenic mice expressing a mutant cardiac troponin T-Gln92: Altered function precedes structural abnormalities
57. Cardiac troponin T mutations results in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy
58. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy: A population-based study in Olmsted County, Minnesota, 1975-1984
59. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy
60. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure
61. Desmin mutation responsible for idiopathic dilated cardiomyopathy
62. A structural scaffolding of IFs in health and disease
63. X-linked dilated cardiomyopathy
64. Evidence for a dystrophin missense mutation as a cause of X-linked dilated cardiomyopathy (XLCM)
65. Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin
66. An aditional exon in the human vinculin gene specifically encodes meta-vinculin-specific difference peptide. Cross-species comparison reveals variable and conserved mtifs in the meta-vinculin insert
67. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy
68. MLP-deficient mice exhibit a disruption of cardiac cytarchitectural organization, dilated cardiomyopathy, and heart failure
69. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy
70. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress
71. Enhanced Galphq signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure
72. Monocyte chemoattractant protein 1 (MCP-1) gene expression in dilated cardiomyopathy
73. Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy
74. Right ventricular cardiomyopathy and sudden death in young people
75. Right ventricular dysplasia: A need for precise pathological definition for interpretation of sudden death